CD274 and melanoma: Our results illustrated that in patients with metastatic urothelial cancer and melanoma, there was a higher expression level of HIC1 in patients with no-response to PD-1/PD-L1 inhibitors, suggesting that HIC1 may serve as a promising biomarker for predicting the immunotherapy efficacy in melanoma and urothelial cancer.